泰恩康：CKBA有望成为国内首个玫瑰痤疮1类创新药，争取2027年底前完成III期临床

Core Viewpoint - The company TianKang has indicated that the development progress of the rosacea indication is faster than that of pediatric vitiligo, and it is expected to be the first indication for CKBA to submit a registration application [1] Group 1: Development Progress - The rosacea indication has over 50 million patients in China with a strong willingness to pay [1] - The company aims to complete Phase III clinical trials by the end of 2027 [1] Group 2: Market Opportunity - There are currently few innovative drug developments globally for this indication [1] - If clinical data is favorable, the drug could become the first Class 1 innovative drug for this indication in China [1]